Saturday 17 October 2026 Export XERS’s income statement to Excel — free account

Xeris Biopharma Holdings, Inc.

XERS Healthcare Drug Manufacturers Specialty & Generic

Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024. In the quarter to June 2026, revenue grew 28.7%, EPS fell 1,700.0%, free cash flow grew 8,403.1% and total debt rose 15.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

10.31 0.24 +2.38%

Follow XERS

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: 54.5×
Dividend yield: —
F-score: 8/9
Altman Z: 0.98
Beneish M: −2.58
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 5.35

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	3	3	1	2	1	1	5	3	3	4	3

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,840.00

Revenue 335.41

Net Income (17.16)

Free Cash Flow 55.67

Net Debt 130.84

Current Ratio 1.45

Debt/Equity (25.95)

P/E ratio 0.00

Fwd P/E 54.50

P/S ratio 5.30

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 55.91%

Next Y EPS Growth 6,785.72%

Next Y revenue growth 32.91%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 61.01%

10-year low 10-year high

EV/Sales against its own 10 years 63.70%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	72	72	111	122
Receivables	39	40	51	58
Inventory	39	48	69	81
Other	—	—	—	—
	156	168	240	275

	2023	2024	2025	Q'26
Payables	12	2	3	9
ST’ Debt	—	15	—	64
Other	20	1	5	5
	95	100	110	190

Compound Annual Growth %

	10y	5y	3y
Sales	—	70.20%	38.33%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(16.52%)	(32.84%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	83	92	—	—	—
’25	60	72	74	86	292
’24	41	48	54	60	203
’23	33	38	48	44	164
’22	22	25	30	33	110
’21	8	9	11	21	50
’20	2	2	9	7	20

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	10	8	—	—	—
’25	(10)	0	18	20	29
’24	(20)	(10)	(8)	2	(37)
’23	(26)	(14)	(15)	7	(47)
’22	(48)	(21)	(18)	(16)	(103)
’21	(24)	(20)	(23)	(29)	(96)
’20	(29)	(24)	(17)	(11)	(81)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	10	8	—	—	—
’25	(10)	0	18	20	28
’24	(20)	(11)	(8)	2	(38)
’23	(26)	(15)	(15)	7	(49)
’22	(48)	(21)	(18)	(16)	(103)
’21	(24)	(20)	(23)	(29)	(97)
’20	(29)	(24)	(17)	(11)	(81)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.01	(0.18)	—	—	—
’25	(0.06)	(0.01)	0.00	0.06	0.00
’24	(0.14)	(0.10)	(0.11)	(0.03)	(0.37)
’23	(0.12)	(0.14)	(0.09)	(0.10)	(0.45)
’22	(0.25)	(0.19)	(0.16)	(0.10)	(0.70)
’21	(0.30)	(0.41)	(0.39)	(0.42)	(1.55)
’20	(0.89)	(0.63)	(0.35)	(0.41)	(2.14)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	15.01	6.81	1.42	1.77	1.14	0.97	1.69	3.14	Analyst estimates 2026–2028 Powerpack
	High	—	—	27.98	18.88	7.24	7.94	3.10	3.07	3.87	10.08
People
People	Employees	—	55	90	202	180	294	355	377	394	435
	Revenue/emp, $m	0.00	0.03	0.03	0.01	0.11	0.17	0.31	0.43	0.52	0.67
Income, $m
Income, $m	Revenue	1	2	2	3	20	50	110	164	203	292
	Gross margin, %	99.26	99.74	100.00	41.11	54.35	73.14	79.47	82.52	81.86	85.41
	EBT	(13)	(27)	(60)	(126)	(91)	(123)	(96)	(64)	(57)	1
	EBT margin, %	(1,228.74)	(1,706.56)	(2,479.57)	(4,630.35)	(446.54)	(247.48)	(87.15)	(38.74)	(28.12)	0.19
	Net income	(13)	(27)	(60)	(126)	(91)	(123)	(95)	(62)	(55)	1
	Depreciation	0	0	1	2	2	3	14	15	16	16
Per share, $
Per share, $	Revenue	0.58	0.77	0.20	0.10	0.48	0.63	0.81	1.19	1.38	1.82
	Earnings	(7.17)	(13.09)	(4.99)	(4.81)	(2.14)	(1.55)	(0.70)	(0.45)	(0.37)	0.00
	Cash flow	(8.73)	(12.16)	(4.67)	(4.00)	(1.89)	(1.21)	(0.76)	(0.34)	(0.25)	0.18
	Capex	(0.02)	(0.35)	(0.13)	(0.04)	(0.01)	(0.01)	0.00	(0.02)	(0.01)	0.00
	Free cash flow	(8.75)	(12.51)	(4.80)	(4.04)	(1.90)	(1.22)	(0.76)	(0.36)	(0.26)	0.17
	Book value	16.81	19.75	6.26	0.55	0.79	1.21	0.33	(0.05)	(0.20)	0.09
	Shares, m	2	2	12	26	43	79	136	138	147	160
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,065.79
	P/S	0.00	0.00	84.52	67.63	10.27	4.67	1.38	1.91	2.45	4.32
	P/B	0.00	0.00	2.72	12.75	6.21	2.43	3.36	0.00	0.00	92.00
	EV/Sales	0.00	0.00	51.19	62.39	8.13	4.44	1.98	2.64	3.24	4.73
	EV/FCF	(0.35)	(0.35)	(2.15)	(1.61)	(2.05)	(2.28)	(2.11)	(8.79)	(17.39)	49.43
Cash, $m
Cash, $m	Operating cash flow	(16)	(25)	(56)	(104)	(81)	(96)	(103)	(47)	(37)	29
	Capex	0	(1)	(2)	(1)	0	(1)	(1)	(2)	(1)	(1)
	Free cash flow	(16)	(25)	(58)	(105)	(81)	(97)	(103)	(49)	(38)	28
Balance, $m
Balance, $m	Working capital	31	39	108	60	124	64	113	61	67	131
	Total debt	—	—	32	58	87	88	189	191	232	220
	Net debt	(32)	(42)	(81)	(17)	(47)	(14)	67	118	160	109
	Shareholders’ equity	31	40	75	14	34	95	45	(7)	(30)	14
Returns, %
Returns, %	ROA	(33.64)	(67.63)	(72.81)	(109.67)	(67.98)	(52.95)	(29.18)	(18.66)	(16.99)	0.16
	ROIC	0.00	0.00	0.00	0.00	0.00	(89.00)	(45.78)	(24.63)	(16.07)	12.65
	ROE	29.43	59.16	(683.66)	(279.56)	(378.20)	(190.28)	(134.83)	(324.20)	301.32	(6.96)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PBH Prestige Consumer Healthcare Inc.	$2.3B	13.9×	10.3×	+6.48% (above 0%: growing)	−36.46% (below 0%: shrinking)	−14.19% (below 0%: shrinking)	51.25%	19.77%	Compare
SUPN Supernus Pharmaceuticals, Inc.	$2.3B	— (loss-making)	103×	+32.40% (above 0%: growing)	n/m	−109.26% (below 0%: shrinking)	84.63%	(26.46%)	Compare
PRGO Perrigo Company plc	$2.3B	— (loss-making)	— (loss-making)	−3.17% (below 0%: shrinking)	n/m	+18.37% (above 0%: growing)	30.69%	2.31%	Compare
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
PAHC Phibro Animal Health Corporation	$1.5B	15.8×	11.1×	+4.77% (above 0%: growing)	+28.57% (above 0%: growing)	−35.73% (below 0%: shrinking)	33.88%	12.14%	Compare
ETON Eton Pharmaceuticals, Inc.	$1.5B	107×	40.3×	+98.59% (above 0%: growing)	n/m	−8.78% (below 0%: shrinking)	67.61%	34.04%	Compare
Median of peers	$2.1B	15.4×	12.8×	+29.14%	+28.57%	−18.19%	59.41%	13.68%

All 86 Drug Manufacturers Specialty & Generic stocks →

Xeris Biopharma Holdings, Inc. (XERS) key facts

Strength: Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
Xeris Biopharma Holdings, Inc. (XERS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, XERS traded at $10.31, a market capitalization of $1.8 billion.
Return on equity was −6.96% and debt-to-equity -25.95.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 0.98 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.